Fibrocystic Breast Disease (FCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Fibrocystic Breast Disease (FCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Description:
Indication
name: Fibrocystic Breast Disease (FCD)
·
Fibrocystic breast disease (FCD), a prevalent
non-cancerous condition affecting many women globally, falls under benign breast
diseases. These conditions encompass non-malignant abnormalities such as
tumors, trauma, mastalgia, and nipple discharge. The development of benign
breast disease is closely associated with the use of estrogen and anti-estrogen
therapies in women. The process of mammary gland development, maturation, and
differentiation is influenced by hormonal and growth factor changes, which
impact the stromal and epithelial cells. During the late proliferative phase,
the glandular tissue may progress to hyperplastic stages like sclerosing
adenosis or lobular hyperplasia. Hyperplasia, particularly when associated with
a 2% prevalence of Ki67 cells, indicates a twofold increased risk of developing
breast cancer. Proliferative lesions exhibit a 1.3 to 1.9 times higher
likelihood of malignancy in both breasts. Consequently, any increase in
pleomorphic calcifications observed on mammograms should prompt a follow-up
regime with intervals of six months. In cases with multiple small lumps
unsuitable for surgical removal, the initial treatment approach for fibrocystic
breast disease typically focuses on managing the associated symptoms.
Mastectomy is commonly employed when necessary.
·
It is most common between the ages of 30 and
50..
Thelansis’s “Fibrocystic Breast
Disease (FCD) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Fibrocystic Breast Disease (FCD)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Fibrocystic Breast Disease (FCD) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Fibrocystic Breast Disease (FCD) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment